Clinical Trial Update: A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies [Phase 1]

View source ↗

Summary

Pfizer's Maplirpacept (PF-07901801) Phase 1 trial in hematologic malignancies (lymphoma and multiple myeloma) has completed enrollment/status; no efficacy data …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Maplirpacept (PF-07901801)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, Multiple Myeloma | Phase 1 | Status: COMPLETED